Therefore, the significance of HB-EGF as a biomarker of LPA1 activity in other pathologies, such as tissue fibrosis [14], [25], obesity [41], rheumatoid arthritis [15], osteoporosis [5], and neuropathic pain [42], remains to be determined. This evidence concerns the gene LPAR1 and obesity disorder.